Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030

icon1
USD 30.74 BN
MARKET SIZE, 2030
icon2
CAGR 9.6%
(2025-2030)
icon3
540
REPORT PAGES
icon4
770
MARKET TABLES

OVERVIEW

Molecular Diagnostics Market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The molecular diagnostics market is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030, at a CAGR of 9.6% during the forecast period. The molecular diagnostics market is experiencing significant growth, driven by a combination of technological advancements and rising healthcare needs. The increasing prevalence of infectious diseases, cancer, and genetic disorders is further fueling the demand for accurate and early diagnostic solutions. Technological innovations in PCR, next-generation sequencing (NGS), and isothermal amplification have enhanced test speed, sensitivity, and versatility, supporting broader clinical adoption. Additionally, expanding access to healthcare in emerging markets, increasing investment in research and development, and rising awareness of preventive health are further contributing to market expansion

KEY TAKEAWAYS

  • By Product & Service
    The market is segmented into reagents & kits, instruments, and services & software. Reagents & kits lead the market as consumables with recurring demand and widespread use across infectious disease, oncology, genetic, and prenatal testing. Rising emphasis on early detection and preventive care further supports this segment.
  • By Test Type
    The market is segmented into lab tests and PoC tests. Lab tests dominate due to centralized laboratories’ high throughput, accuracy, and suitability for complex applications. Automation, multiplex technologies, and integration into hospital workflows reinforce their leading position.
  • By Sample Type
    The molecular diagnostics market is segmented into blood, serum & plasma, urine, and other sample types. The blood, serum, and plasma segment accounts for the largest share due to its high sensitivity and specificity in detecting viral infections and oncological conditions. Their stability during transportation and storage, along with growing use of biomarkers in personalized medicine, further drives demand for these sample types.
  • By Technology
    The molecular diagnostics market is categorized into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. PCR is estimated to account for the largest share, driven by its high sensitivity, specificity, and broad clinical adoption. Its versatility across routine diagnostics, outbreak management, and both centralized and decentralized settings makes it the most trusted and widely used technology.
  • By Application
    The molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Infectious disease diagnostics are estimated to lead due to rising prevalence, advanced assays, and expanding healthcare infrastructure. This segment benefits from the global focus on early detection and effective management of infectious diseases.
  • By Technique
    The market is segmented into multiplex testing and singleplex testing. Multiplex testing is set to dominate as it allows simultaneous detection of multiple targets, improving efficiency and turnaround time. Its adoption is driven by syndromic testing, point-of-care platforms, and technological advances in PCR and NGS.
  • By Clinical Application
    The market is segmented into diagnostic and screening. The diagnostics segment is estimated to be larger due to its critical role in detecting infectious diseases, cancer, and genetic disorders. Continuous improvements in PCR, NGS, and point-of-care platforms enhance accuracy, speed, and accessibility.
  • By End User
    The molecular diagnostics market is categorized into diagnostic laboratories, hospitals & clinics, and other end users. Diagnostic laboratories account for the largest share, driven by rising test volumes for infectious diseases, cancer, and genetic disorders. Their advanced instruments, high-throughput platforms, skilled personnel, and ability to quickly adopt innovative assays make them the preferred choice for accurate and timely testing, including in emerging markets.
  • By Region
    North America is projected to lead the molecular diagnostics market, driven by advanced healthcare infrastructure and high test adoption rates. The Asia Pacific region is set to emerge as the fastest-growing market due to improving diagnostic capabilities and expanding healthcare access.
  • Competitive Landscape
    Major players in the molecular diagnostics market have adopted both organic and inorganic strategies, including partnerships, product launches, and acquisitions. Danaher Corporation and F. Hoffmann-La Roche Ltd. are among the leading players in this market. 

Government investments in precision medicine and genomics are accelerating the adoption of molecular diagnostic kits and instruments. Alongside this, the increasing incidence of infectious diseases and cancer is a major factor driving market growth. The rising number of hospitals across both developed and emerging regions, supported by a growing patient base, is further strengthening the demand for precise molecular testing. In addition, advancements in technology, especially in portability and faster turnaround times, are enabling smaller healthcare facilities to integrate molecular-based testing more effectively into their operations.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The growing burden of infectious diseases is expected to be a key driver of the molecular diagnostics market. However, many OEMs are currently overlooking opportunities in the point-of-care (POC) molecular diagnostics segment. As the field continues to advance, new application areas are emerging that highlight significant potential for future growth. In oncology, molecular diagnostics have transformed cancer care by enabling earlier detection, precise subtyping, and effective monitoring of treatment response. Next-generation sequencing (NGS) has further strengthened oncology testing by allowing the simultaneous analysis of multiple genes and delivering comprehensive genetic insights. NGS also supports the identification of targetable mutations and the detection of rare or novel genetic alterations, guiding more personalized treatment decisions. This ongoing shift toward advanced technologies is expected to reshape the revenue mix for companies in the molecular diagnostics market over the next three to five years.

Molecular Diagnostics Market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing prevalence of infectious diseases and cancer
  • Growing R&D funding
RESTRAINTS
Impact
Level
  • Inadequate reimbursements
  • High cost of molecular diagnostic instruments
OPPORTUNITIES
Impact
Level
  • Growing significance of companion diagnostics
  • Rising disposable income and medical tourism in emerging economies
CHALLENGES
Impact
Level
  • Changing regulatory landscape
  • Operational barriers and labor shortage

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing R&D funding

Growing R&D funding is emerging as a key driver of the molecular diagnostics market, with government initiatives, targeted funding schemes, and supportive policy frameworks playing a pivotal role. Many countries are implementing programs that offer financial incentives, tax benefits, and infrastructure support to both private companies and research institutions. These measures are designed to stimulate innovation and foster the development of advanced diagnostic technologies. Increased R&D investments are enabling the exploration of advanced platforms such as next-generation sequencing, digital PCR, and multiplex assays, while also enhancing laboratory capabilities. In addition, government-backed grants and public-private partnerships are creating opportunities for collaborative projects that speed up product development cycles. This proactive approach not only facilitates the creation of highly sensitive and specific diagnostic solutions but also contributes to improving their accessibility and cost-effectiveness in diverse healthcare settings. These efforts contribute to earlier disease detection, better patient management, and improved disease monitoring. Overall, sustained R&D investment is fostering steady innovation, expanding the range of available tests, and helping healthcare systems meet the growing demand for timely and accurate diagnostic solutions.

Restraint: High cost of molecular diagnostic instruments

High cost is a major restraint in the molecular diagnostics market, particularly for instruments used in advanced testing. These devices are developed using specialized technology and meet strict quality requirements, making them expensive to manufacture and purchase. As a result, they are mainly affordable for large hospitals and well-funded reference laboratories with the capital to invest in such equipment. Smaller laboratories, community clinics, and individual healthcare providers often lack the financial resources to buy these instruments. In addition to the high purchase price, there are ongoing expenses such as maintenance, calibration, software updates, and the cost of consumables required for each test. Training healthcare staff to operate the instruments and meeting compliance requirements further adds to the total cost. These recurring expenses make it challenging for smaller facilities to adopt advanced molecular testing. This cost barrier can lead to unequal access, with patients in rural or underserved areas relying on slower or less accurate testing methods. Overall, the high cost of molecular diagnostic instruments limits market penetration and delays the availability of faster and more reliable diagnostic solutions for many healthcare settings.

Opportunity: Rising disposable income and medical tourism in emerging economies

Emerging economies such as Brazil and India offer significant growth opportunities for the molecular diagnostics market. These countries face a high burden of infectious and chronic diseases, creating strong demand for accurate and timely diagnostic solutions. Large patient populations and a growing awareness of early disease detection are further driving adoption. Rising disposable incomes are enabling more people to afford advanced diagnostic services, while the expansion of private healthcare facilities is improving accessibility. In addition, increasing medical tourism in countries like India, South Korea, and Mexico is boosting the need for high-quality and reliable diagnostics to serve both domestic and international patients. At the same time, governments and private investors are making significant investments in life sciences research and healthcare infrastructure, with particular attention to the expansion and modernization of laboratory facilities. Such improvements are enabling faster integration of advanced diagnostic technologies into routine healthcare. Thus, the combination of growing healthcare demand, improved infrastructure, and supportive investments is accelerating the adoption of molecular diagnostics in emerging economies, making them attractive markets for industry players seeking long-term growth opportunities.

Challenge: Changing regulatory landscape

The molecular diagnostics market is facing significant challenges due to the constantly changing regulatory landscape across different regions. Regulatory authorities frequently update guidelines, compliance requirements, and quality standards to ensure the safety, accuracy, and reliability of diagnostic products. These changes can create delays in product approvals and extend development timelines, particularly for innovative technologies. Companies operating in this market must regularly adapt their products, processes, and documentation to align with new regulatory expectations. This often requires additional investment in research, validation studies, and quality management systems, increasing both cost and resource demands. For organizations seeking to expand globally, the situation becomes even more complex, as each country or region may have its own specific regulatory framework, approval process, and documentation requirements. Navigating these varying rules can slow down market entry and limit the speed of product launches. Moreover, smaller companies may face greater challenges, as they often lack the resources to manage frequent regulatory changes efficiently. This evolving regulatory environment adds uncertainty and operational complexity, requiring companies to develop strategies to meet diverse requirements while maintaining innovation and competitiveness.

Molecular Diagnostics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Advanced molecular diagnostic platforms across PCR, NGS, and immunoassays Higher testing accuracy, scalable automation, and improved laboratory efficiency
Integrated molecular diagnostics for oncology and infectious diseases Early disease detection, personalized treatment guidance, and broader patient access
Next-generation sequencing (NGS) technologies for clinical and research applications Comprehensive genomic insights, detection of rare mutations, and precision medicine support
Molecular testing solutions with a strong focus on women’s health Faster results, enhanced diagnostic reliability, and improved patient outcomes
Molecular diagnostics and microbiology solutions for infectious disease detection Rapid pathogen identification, better outbreak management, and optimized clinical workflows

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The molecular diagnostics market caters to a broad range of end users, including hospitals and clinics, diagnostic laboratories, and other end users. It is segmented by various technologies such as polymerase chain reaction (PCR), isothermal nucleic acid amplification, DNA sequencing and next-generation sequencing (NGS), in situ hybridization, DNA microarrays, and other technologies. The adoption of these technologies across end users is driven by continuous advancements in diagnostic tools and a rising number of regulatory approvals. Within this ecosystem, product manufacturers play a critical role in designing, developing, and supplying high-quality diagnostic instruments, reagents, and consumables. They focus on innovation, accuracy, and efficiency while ensuring products meet required safety and performance standards. End users, including diagnostic laboratories, hospitals, and clinics are responsible for implementing these technologies in clinical practice to provide timely and accurate diagnosis, guide treatment decisions, and support disease monitoring. Regulatory bodies set and enforce guidelines, assess product safety and efficacy, and grant necessary approvals for market entry. Their oversight ensures diagnostic products meet quality standards, safeguard patient health, and maintain trust in testing outcomes, ultimately shaping market growth and adoption.

Molecular Diagnostics Market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Molecular Diagnostics Market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Molecular Diagnostics Market, by Product & Service

The global molecular diagnostics market is segmented into reagents & kits, instruments, and services & software. The reagents & kits segment represented the largest segment of the molecular diagnostics market, primarily because these products are consumables that are required in high volumes for each diagnostic test, ensuring recurring demand. They are widely used across diverse applications such as infectious disease testing, oncology, genetic testing, and prenatal diagnostics, which further supports their dominance. In addition, the rising global emphasis on early disease detection and prevention has significantly boosted the use of molecular diagnostic reagents and kits, as patients and healthcare providers increasingly recognize the value of timely, accurate testing in improving treatment outcomes and reducing long-term healthcare costs.

Molecular Diagnostics Market, by Test Type

By test type, the molecular diagnostics market is divided into lab tests and PoC tests. The lab tests segment accounted for the largest market. This is primarily due to the widespread use of molecular testing in centralized laboratories, which handle high patient volumes and require advanced, high-throughput platforms. Lab tests offer superior accuracy, sensitivity, and broad assay menus, which make them suitable for complex applications, such as cancer diagnostics, genetic screening, and infectious disease detection. These tests are well-integrated into hospital and reference lab workflows, supported by trained personnel and quality control protocols. The continued development of automated systems and multiplex technologies further enhances lab testing efficiency. Their established infrastructure and clinical reliability continue to drive their dominance in the market.

Molecular Diagnostics Market, by Sample Type

By sample type, the molecular diagnostics market is segmented into blood, serum, and plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share of the market. This is attributed to the high sensitivity and specificity these sample types offer in detecting a wide range of diseases, including viral infections and oncological conditions. Their stability during transportation and storage makes them ideal for both centralized laboratories and point-of-care settings. Additionally, the growing adoption of personalized medicine and increased use of biomarkers in clinical decision-making are further fueling the demand for blood-based molecular testing. These advantages collectively position the segment for continued strong growth.

Molecular Diagnostics Market, By Technology

By Technology, the molecular diagnostics market is categorized into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. PCR held the largest share of the market, driven by its high sensitivity, specificity, and broad clinical adoption. It is widely applied in diagnosing infectious diseases, genetic disorders, and certain cancers, delivering rapid and reliable results. Its adaptability from routine diagnostic testing to managing outbreak situations has strengthened its presence across both centralized laboratories and decentralized settings. With growing demand for fast and accurate diagnostic solutions, PCR continues to be the most trusted and extensively used technology in molecular diagnostics.

Molecular Diagnostics Market, by Application

Based on applications, the molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. Among these, the infectious disease diagnostics segment holds the largest share. This dominance is driven by the development of advanced assays capable of accurately diagnosing a wide range of diseases and conditions, the growing prevalence of infectious diseases, and increasing awareness of the benefits of molecular diagnostic technologies in controlling their spread. Infectious diseases continue to pose a major public health challenge globally, with frequent outbreaks and epidemics. Timely and precise identification of infectious agents is critical for guiding appropriate treatment, implementing effective infection control measures, and supporting preventive interventions. In addition, the expansion of healthcare infrastructure in low- and middle-income countries is accelerating the adoption of molecular diagnostics for infectious diseases, facilitating earlier detection and improving overall health outcomes.

Molecular Diagnostics Market, by Technique

Based on technique, the molecular diagnostics market is segmented into multiplex testing and singleplex testing. The multiplex testing segment holds the largest share, driven by its ability to detect multiple targets in a single reaction, which enhances diagnostic efficiency and reduces turnaround time. This capability is particularly valuable in applications such as infectious disease panels, genetic screening, and oncology, where multiple markers must be evaluated simultaneously. The growing demand for syndromic testing, coupled with the expansion of point-of-care molecular platforms, is accelerating the adoption of multiplex assays in both clinical and decentralized settings. Advances in PCR and next-generation sequencing (NGS) technologies are further improving multiplex assay performance, enabling higher throughput and greater accuracy. Moreover, the increasing emphasis on cost-effective diagnostics in resource-limited environments is supporting the shift toward multiplex solutions.

Molecular Diagnostics Market, by Clinical Application

Based on clinical application, the molecular diagnostics market is segmented into diagnostic and screening. The diagnostic segment held the largest share, largely due to its critical role in detecting and confirming infectious diseases, cancer, and genetic disorders. Continuous advancements in technologies such as PCR, next-generation sequencing (NGS), and point-of-care molecular platforms are enhancing diagnostic accuracy, speed, and accessibility. These developments collectively reinforce the diagnostic segment’s leading position in the molecular diagnostics market.

Molecular Diagnostics Market, by End User

By end user, the molecular diagnostics is categorized into diagnostic laboratories, hospitals & clinics, and other end users. The diagnostic laboratories segment accounted for the largest market. This leading position is primarily driven by the increasing test volumes for infectious diseases, cancer, and genetic disorders, as well as the growing need for accurate and timely diagnosis. Many healthcare providers outsource complex molecular testing to these labs due to their cost-effectiveness, advanced instruments, high-throughput platforms, and skilled personnel. Their ability to quickly adopt innovative assays and expand in emerging markets further strengthens their position, ensuring diagnostic laboratories remain the leading end-user segment

REGION

Asia Pacific to be fastest-growing region in global molecular diagnostics market during forecast period

Asia Pacific is projected to witness the most rapid growth in the global molecular diagnostics market during the forecast period. This growth is supported by the rising healthcare investments, growing awareness of early disease detection, and increasing adoption of advanced diagnostic technologies across emerging economies. Countries such as China, India, and South Korea are experiencing rapid improvements in healthcare infrastructure and laboratory capacity. In addition, government initiatives aimed at strengthening infectious disease surveillance and expanding access to molecular testing are contributing to market growth. The large patient population and rising demand for personalized healthcare solutions further reinforce the region’s growth potential.

Molecular Diagnostics Market Region

Molecular Diagnostics Market: COMPANY EVALUATION MATRIX

In the molecular diagnostics market, Danaher Corporation (US) leads with a strong market presence and a broad portfolio of innovative diagnostic solutions. The company’s advanced technologies, extensive global reach, and continuous investment in R&D drive large-scale adoption across key areas such as infectious diseases and oncology, solidifying its position in the market.

Molecular Diagnostics Market Evaluation Matrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size, 2024 (Value) USD 18.29 Billion
Market Forecast, 2030 (Value) USD 30.74 Billion
Growth Rate CAGR of 9.6% from 2025 to 2030
Years Considered 2023–2030
Base year 2024
Forecast period 2025–2030
Units considered Value (USD Million/Billion), Volume (Million)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • Product & Service:
    • Reagents & Kits
    • Instruments
    • Services & Software
  • Test Type:
    • Lab Tests
    • PoC Tests
  • Sample Type:
    • Blood
    • Serum
    • and Plasma; Urine; and Other Sample Types
  • Technology:
    • Polymerase Chain Reaction
    • Isothermal Nucleic Acid Amplification Technology
    • DNA Sequencing & Next-generation Sequencing
    • In Situ Hybridization
    • DNA Microarrays
    • Other Technologies
  • Application:
    • Infectious Disease Diagnostics
    • Oncology Testing
    • Genetic Testing
    • Other Applications
  • Technique:
    • Multiplex Testing
    • Singleplex Testing
  • Clinical Application:
    • Diagnostic
    • Screening
  • End User:
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Other End Users
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: Molecular Diagnostics Market REPORT CONTENT GUIDE

Molecular Diagnostics Market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Product matrix, which provides a detailed comparison of the product portfolio of each company in the molecular diagnostics market Enables easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities
Company Information Additional five company profiles of players operating in the molecular diagnostics market Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning
Geographic Analysis Additional country-level analysis of the molecular diagnostics market Guides market entry, localization, and targeted launch strategies by highlighting regional demand and opportunities

RECENT DEVELOPMENTS

  • June 2025 : Health Canada issued Cepheid (a subsidiary of Danaher Corporation (US)) a medical device license for Xpert HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels.
  • May 2025 : Illumina, Inc. (US) received approval from the Ministry of Health, Labour and Welfare (MHLW) for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device) in Japan.
  • February 2025 : bioMérieux (France) obtained clearance for its BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid from the US FDA. This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in approximately one hour.
  • January 2025 : F. Hoffmann-La Roche Ltd. (Switzerland) received the US FDA 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels that diagnose sexually transmitted infections at the point of care.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
48
2
RESEARCH METHODOLOGY
 
 
 
53
3
EXECUTIVE SUMMARY
 
 
 
66
4
PREMIUM INSIGHTS
 
 
 
73
5
MARKET OVERVIEW
Explore dynamic growth opportunities in molecular diagnostics amid technological advances and regulatory shifts.
 
 
 
78
 
5.1
INTRODUCTION
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
5.2.1.1
Increasing prevalence of infectious diseases and cancer
 
 
 
 
5.2.1.2
Growing R&D funding
 
 
 
 
5.2.1.3
Surge in technological advancements
 
 
 
 
5.2.1.4
Rising use of point-of-care diagnostic tests
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
5.2.2.1
Inadequate reimbursements
 
 
 
 
5.2.2.2
High cost of molecular diagnostic instruments
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
5.2.3.1
Growing significance of companion diagnostics
 
 
 
 
5.2.3.2
Increasing growth opportunities in emerging economies
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
5.2.4.1
Changing regulatory landscape
 
 
 
 
5.2.4.2
Operational barriers and labor shortage
 
 
 
 
5.2.4.3
Introduction of alternative technologies
 
 
5.3
PRICING ANALYSIS
 
 
 
 
 
 
5.3.1
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS
 
 
 
 
5.3.2
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER
 
 
 
 
5.3.3
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION
 
 
 
5.4
PATENT ANALYSIS
 
 
 
 
 
 
5.4.1
LIST OF MAJOR PATENTS
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.6
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
5.7
HS CODES
 
 
 
 
 
 
5.7.1
IMPORT SCENARIO (HS CODE 3822)
 
 
 
 
5.7.2
EXPORT SCENARIO (HS CODE 3822)
 
 
 
5.8
ECOSYSTEM ANALYSIS
 
 
 
 
 
5.9
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.9.1
THREAT FROM NEW ENTRANTS
 
 
 
 
5.9.2
THREAT FROM SUBSTITUTES
 
 
 
 
5.9.3
BARGAINING POWER OF BUYERS
 
 
 
 
5.9.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
5.9.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
5.10
REGULATORY LANDSCAPE
 
 
 
 
 
5.10.1
REGULATORY FRAMEWORK
 
 
 
 
 
5.10.1.1
North America
 
 
 
 
5.10.1.2
Europe
 
 
 
 
5.10.1.3
Asia Pacific
 
 
 
 
5.10.1.4
Latin America
 
 
 
 
5.10.1.5
Middle East
 
 
 
5.10.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
5.11
TECHNOLOGY ANALYSIS
 
 
 
 
 
5.11.1
KEY TECHNOLOGIES
 
 
 
 
 
5.11.1.1
Polymerase chain reaction
 
 
 
5.11.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
5.11.2.1
Microarrays
 
 
 
5.11.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
5.11.3.1
Next-generation sequencing
 
 
5.12
KEY CONFERENCES & EVENTS, 2025–2026
 
 
 
 
5.13
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
5.14
KEY STAKEHOLDERS AND BUYING CRITERIA
 
 
 
 
 
 
5.14.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
5.14.2
BUYING CRITERIA
 
 
 
5.15
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
5.16
CASE STUDY ANALYSIS
 
 
 
 
 
5.16.1
CASE STUDY 1: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
 
 
 
 
5.16.2
CASE STUDY 2: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS AND BED MANAGEMENT
 
 
 
 
5.16.3
CASE STUDY 3: RAPID PCR TESTING STREAMLINED EMERGENCY CARE AND SURGICAL RESOURCE MANAGEMENT IN GERMAN HOSPITAL
 
 
 
5.17
IMPACT OF AI/GENERATIVE AI ON MOLECULAR DIAGNOSTICS MARKET
 
 
 
 
 
 
5.17.1
INTRODUCTION
 
 
 
 
5.17.2
MARKET POTENTIAL OF AI
 
 
 
 
 
5.17.2.1
Key use cases
 
 
 
5.17.3
IMPLEMENTATION OF AI BY KEY COMPANIES
 
 
 
 
5.17.4
FUTURE OF AI IN MOLECULAR DIAGNOSTICS MARKET
 
 
 
5.18
US 2025 TARIFF
 
 
 
 
 
5.18.1
INTRODUCTION
 
 
 
 
5.18.2
KEY TARIFF RATES
 
 
 
 
5.18.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.18.4
IMPACT ON REGION
 
 
 
 
 
5.18.4.1
North America
 
 
 
 
5.18.4.2
Europe
 
 
 
 
5.18.4.3
Asia Pacific
 
 
 
5.18.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
5.18.5.1
Hospitals & clinics
 
 
 
 
5.18.5.2
Diagnostic laboratories
 
6
MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
 
 
 
119
 
6.1
INTRODUCTION
 
 
 
 
6.2
REAGENTS & KITS
 
 
 
 
 
6.2.1
INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION TO PROPEL MARKET
 
 
 
6.3
INSTRUMENTS
 
 
 
 
 
6.3.1
RISING NEED FOR QUICK AND ACCURATE TEST RESULTS TO BOOST MARKET
 
 
 
6.4
SERVICES & SOFTWARE
 
 
 
 
 
6.4.1
GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET
 
 
7
MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
 
 
 
131
 
7.1
INTRODUCTION
 
 
 
 
7.2
LAB TESTS
 
 
 
 
 
7.2.1
INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET
 
 
 
7.3
POC TESTS
 
 
 
 
 
7.3.1
INCREASED INVESTMENT BY PUBLIC HEALTH AGENCIES AND GOVERNMENTS TO BOOST MARKET
 
 
8
MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
 
 
 
140
 
8.1
INTRODUCTION
 
 
 
 
8.2
BLOOD, SERUM, AND PLASMA
 
 
 
 
 
8.2.1
INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET
 
 
 
8.3
URINE
 
 
 
 
 
8.3.1
NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET
 
 
 
8.4
OTHER SAMPLE TYPES
 
 
 
9
MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 48 Data Tables
 
 
 
152
 
9.1
INTRODUCTION
 
 
 
 
9.2
POLYMERASE CHAIN REACTION
 
 
 
 
 
9.2.1
RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH
 
 
 
9.3
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
 
 
 
 
 
9.3.1
NEED FOR PROMPT DIAGNOSIS TO STIMULATE GROWTH
 
 
 
9.4
DNA SEQUENCING & NEXT-GENERATION SEQUENCING
 
 
 
 
 
9.4.1
GROWING TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
 
 
 
9.5
IN SITU HYBRIDIZATION
 
 
 
 
 
9.5.1
RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES AND GENE MAPPING TO BOOST MARKET
 
 
 
9.6
DNA MICROARRAYS
 
 
 
 
 
9.6.1
SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET
 
 
 
9.7
OTHER TECHNOLOGIES
 
 
 
10
MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 191 Data Tables
 
 
 
176
 
10.1
INTRODUCTION
 
 
 
 
10.2
INFECTIOUS DISEASE DIAGNOSTICS
 
 
 
 
 
10.2.1
SEXUALLY TRANSMITTED DISEASES
 
 
 
 
 
10.2.1.1
CT/NG
 
 
 
 
10.2.1.2
HIV
 
 
 
 
10.2.1.3
HPV
 
 
 
 
10.2.1.4
Syphilis
 
 
 
 
10.2.1.5
Other sexually transmitted diseases
 
 
 
10.2.2
HEPATITIS
 
 
 
 
 
10.2.2.1
Hepatitis B
 
 
 
 
10.2.2.2
Hepatitis C
 
 
 
 
10.2.2.3
Other hepatitis diseases
 
 
 
10.2.3
RESPIRATORY INFECTIOUS DISEASES
 
 
 
 
 
10.2.3.1
Tuberculosis
 
 
 
 
10.2.3.2
Influenza
 
 
 
 
10.2.3.3
Pharyngitis
 
 
 
 
10.2.3.4
Other respiratory infectious diseases
 
 
 
10.2.4
HOSPITAL-ACQUIRED INFECTIONS
 
 
 
 
 
10.2.4.1
Booming geriatric population to aid growth
 
 
 
10.2.5
VECTOR-BORNE DISEASES
 
 
 
 
 
10.2.5.1
Growing focus on disease surveillance to propel market
 
 
 
10.2.6
OTHER INFECTIOUS DISEASES
 
 
 
10.3
ONCOLOGY TESTING
 
 
 
 
 
10.3.1
BREAST CANCER
 
 
 
 
 
10.3.1.1
Increasing need to improve survival rates to support growth
 
 
 
10.3.2
COLORECTAL CANCER
 
 
 
 
 
10.3.2.1
Rising demand for biomarkers to fuel market
 
 
 
10.3.3
LUNG CANCER
 
 
 
 
 
10.3.3.1
Increasing use of predictive biomarkers to drive market
 
 
 
10.3.4
PROSTATE CANCER
 
 
 
 
 
10.3.4.1
Surge in advancements in genomic technologies to aid growth
 
 
 
10.3.5
OTHER CANCER TYPES
 
 
 
10.4
GENETIC TESTING
 
 
 
 
 
10.4.1
GROWING IMPORTANCE OF DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET
 
 
 
10.5
OTHER APPLICATIONS
 
 
 
11
MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
 
 
 
262
 
11.1
INTRODUCTION
 
 
 
 
11.2
MULTIPLEX TESTING
 
 
 
 
 
11.2.1
RISING DEMAND FOR QUICK DIAGNOSIS TO PROMOTE GROWTH
 
 
 
11.3
SINGLEPLEX TESTING
 
 
 
 
 
11.3.1
NEED FOR AFFORDABLE TESTING TO AUGMENT GROWTH
 
 
12
MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 15 Data Tables
 
 
 
271
 
12.1
INTRODUCTION
 
 
 
 
12.2
DIAGNOSTIC
 
 
 
 
 
12.2.1
INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING AND TIMELY TREATMENT TO DRIVE MARKET
 
 
 
12.3
SCREENING
 
 
 
 
 
12.3.1
GROWING IMPORTANCE OF EARLY INFECTIOUS DISEASE SCREENING TO PROPEL MARKET EXPANSION
 
 
13
MOLECULAR DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 19 Data Tables
 
 
 
279
 
13.1
INTRODUCTION
 
 
 
 
13.2
DIAGNOSTIC LABORATORIES
 
 
 
 
 
13.2.1
INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH
 
 
 
13.3
HOSPITALS & CLINICS
 
 
 
 
 
13.3.1
GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH
 
 
 
13.4
OTHER END USERS
 
 
 
14
MOLECULAR DIAGNOSTICS MARKET, BY REGION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 327 Data Tables
 
 
 
290
 
14.1
INTRODUCTION
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
14.2.1
MACROECONOMIC OUTLOOK
 
 
 
 
14.2.2
US
 
 
 
 
 
14.2.2.1
Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market
 
 
 
14.2.3
CANADA
 
 
 
 
 
14.2.3.1
Growing focus on genomic research to fuel market
 
 
14.3
EUROPE
 
 
 
 
 
14.3.1
MACROECONOMIC OUTLOOK
 
 
 
 
14.3.2
GERMANY
 
 
 
 
 
14.3.2.1
Robust healthcare spending and increasing per capita disposable income to propel market
 
 
 
14.3.3
UK
 
 
 
 
 
14.3.3.1
Expanding community-based diagnostics to drive adoption of molecular diagnostics
 
 
 
14.3.4
FRANCE
 
 
 
 
 
14.3.4.1
Rising R&D expenditure for product launches and development of new technologies to augment growth
 
 
 
14.3.5
ITALY
 
 
 
 
 
14.3.5.1
Growing demographic shift toward elderly population to support market
 
 
 
14.3.6
SPAIN
 
 
 
 
 
14.3.6.1
Surge in demand for genetic and prenatal testing to aid growth
 
 
 
14.3.7
RUSSIA
 
 
 
 
 
14.3.7.1
Increasing access to quality healthcare to boost market growth
 
 
 
14.3.8
SWITZERLAND
 
 
 
 
 
14.3.8.1
Rising healthcare spending for new medications and therapies to drive market
 
 
 
14.3.9
REST OF EUROPE
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
14.4.1
MACROECONOMIC OUTLOOK
 
 
 
 
14.4.2
CHINA
 
 
 
 
 
14.4.2.1
Growing public access to modern healthcare to drive market
 
 
 
14.4.3
JAPAN
 
 
 
 
 
14.4.3.1
Universal healthcare reimbursement policy to support market
 
 
 
14.4.4
INDIA
 
 
 
 
 
14.4.4.1
Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market
 
 
 
14.4.5
AUSTRALIA
 
 
 
 
 
14.4.5.1
Rising technological advancements to stimulate growth
 
 
 
14.4.6
SOUTH KOREA
 
 
 
 
 
14.4.6.1
Favorable government initiatives for promoting medical tourism to support growth
 
 
 
14.4.7
REST OF ASIA PACIFIC
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
14.5.1
MACROECONOMIC OUTLOOK
 
 
 
 
14.5.2
BRAZIL
 
 
 
 
 
14.5.2.1
Universal healthcare access to drive adoption in Brazil
 
 
 
14.5.3
MEXICO
 
 
 
 
 
14.5.3.1
Booming medical tourism industry to aid growth
 
 
 
14.5.4
REST OF LATIN AMERICA
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
14.6.1
MACROECONOMIC OUTLOOK
 
 
 
 
14.6.2
SAUDI ARABIA
 
 
 
 
 
14.6.2.1
Rising government healthcare expenditure to boost market
 
 
 
14.6.3
UAE
 
 
 
 
 
14.6.3.1
Improvements in healthcare infrastructure to support growth
 
 
 
14.6.4
REST OF MIDDLE EAST & AFRICA
 
 
15
COMPETITIVE LANDSCAPE
Gain strategic insights into key players' market dominance and emerging leaders in molecular diagnostics.
 
 
 
436
 
15.1
INTRODUCTION
 
 
 
 
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
 
 
 
15.3
REVENUE SHARE ANALYSIS
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
15.5.1
STARS
 
 
 
 
15.5.2
EMERGING LEADERS
 
 
 
 
15.5.3
PERVASIVE PLAYERS
 
 
 
 
15.5.4
PARTICIPANTS
 
 
 
 
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
15.5.5.1
Company footprint
 
 
 
 
15.5.5.2
Region footprint
 
 
 
 
15.5.5.3
Product & service footprint
 
 
 
 
15.5.5.4
Sample type footprint
 
 
 
 
15.5.5.5
Application footprint
 
 
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 
 
 
 
 
 
15.6.1
PROGRESSIVE COMPANIES
 
 
 
 
15.6.2
RESPONSIVE COMPANIES
 
 
 
 
15.6.3
DYNAMIC COMPANIES
 
 
 
 
15.6.4
STARTING BLOCKS
 
 
 
 
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
15.6.5.1
Detailed list of key startups/SMES
 
 
 
 
15.6.5.2
Competitive benchmarking of startups/SMES
 
 
15.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
15.7.1
FINANCIAL METRICS
 
 
 
 
15.7.2
COMPANY VALUATION
 
 
 
15.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
15.9.1
PRODUCT/SERVICES LAUNCHES AND APPROVALS
 
 
 
 
15.9.2
DEALS
 
 
 
 
15.9.3
EXPANSIONS
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
453
 
16.1
KEY PLAYERS
 
 
 
 
 
16.1.1
DANAHER CORPORATION
 
 
 
 
 
16.1.1.1
Business overview
 
 
 
 
16.1.1.2
Products/Services offered
 
 
 
 
16.1.1.3
Recent developments
 
 
 
 
16.1.1.4
MnM view
 
 
 
16.1.2
F. HOFFMANN-LA ROCHE LTD
 
 
 
 
16.1.3
ILLUMINA, INC.
 
 
 
 
16.1.4
HOLOGIC, INC.
 
 
 
 
16.1.5
BIOMÉRIEUX
 
 
 
 
16.1.6
ABBOTT LABORATORIES
 
 
 
 
16.1.7
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
16.1.8
QIAGEN N.V.
 
 
 
 
16.1.9
REVVITY, INC.
 
 
 
 
16.1.10
MYRIAD GENETICS, INC.
 
 
 
 
16.1.11
SIEMENS HEALTHINEERS AG
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
16.2.1
BECTON, DICKINSON AND COMPANY (BD)
 
 
 
 
16.2.2
GRIFOLS, S.A.
 
 
 
 
16.2.3
QUIDELORTHO CORPORATION
 
 
 
 
16.2.4
DIASORIN S.P.A.
 
 
 
 
16.2.5
EXACT SCIENCES CORPORATION
 
 
 
 
16.2.6
GENETIC SIGNATURES
 
 
 
 
16.2.7
AGILENT TECHNOLOGIES, INC.
 
 
 
 
16.2.8
MDXHEALTH
 
 
 
 
16.2.9
BIOCARTIS
 
 
 
 
16.2.10
MEDIGEN BIOTECHNOLOGY CORP.
 
 
 
 
16.2.11
VELA DIAGNOSTICS
 
 
 
 
16.2.12
AMOY DIAGNOSTICS CO., LTD.
 
 
 
 
16.2.13
BRUKER CORPORATION (ELITECHGROUP)
 
 
 
 
16.2.14
MOLBIO DIAGNOSTICS LIMITED
 
 
 
 
16.2.15
GENEOMBIOTECHNOLOGIES
 
 
 
 
16.2.16
SAVYON DIAGNOSTICS
 
 
 
 
16.2.17
UNIOGEN OY
 
 
17
APPENDIX
 
 
 
530
 
17.1
DISCUSSION GUIDE
 
 
 
 
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
17.3
CUSTOMIZATION OPTIONS
 
 
 
 
17.4
RELATED REPORTS
 
 
 
 
17.5
AUTHOR DETAILS
 
 
 
LIST OF TABLES
 
 
 
 
 
TABLE 1
MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
 
 
 
 
TABLE 2
MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
 
 
 
 
TABLE 3
TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
 
 
 
 
TABLE 4
NUMBER OF CANCER PATIENTS WORLDWIDE, BY REGION, 2022 VS. 2035 VS. 2045
 
 
 
 
TABLE 5
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, 2023–2025 (USD)
 
 
 
 
TABLE 6
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC REAGENTS & KITS, BY KEY PLAYER, 2023–2025 (USD)
 
 
 
 
TABLE 7
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025 (USD)
 
 
 
 
TABLE 8
LIST OF MAJOR PATENTS, 2022–2024
 
 
 
 
TABLE 9
IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION)
 
 
 
 
TABLE 10
EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION)
 
 
 
 
TABLE 11
MOLECULAR DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
TABLE 12
IMPACT OF PORTER’S FORCES ON MOLECULAR DIAGNOSTICS MARKET
 
 
 
 
TABLE 13
CLASSIFICATION OF IVD DEVICES IN EUROPE
 
 
 
 
TABLE 14
TIME, COST, AND COMPLEXITY OF DEVICE REGISTRATION PROCESS IN JAPAN
 
 
 
 
TABLE 15
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 16
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 17
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 18
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 19
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 20
MOLECULAR DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026
 
 
 
 
TABLE 21
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
 
 
 
 
TABLE 22
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
 
 
 
 
TABLE 23
RECIPROCAL TARIFF RATES ADJUSTED BY US
 
 
 
 
TABLE 24
MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 25
KEY REAGENTS AND KITS AVAILABLE IN MARKET
 
 
 
 
TABLE 26
MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 27
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 28
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 29
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 30
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 31
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 32
KEY INSTRUMENTS AVAILABLE IN MARKET
 
 
 
 
TABLE 33
MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 34
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 35
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 36
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 37
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 38
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 39
KEY SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE
 
 
 
 
TABLE 40
MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 41
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 42
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 43
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 44
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 45
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 46
MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 47
KEY LABORATORY TESTING INSTRUMENTS AVAILABLE IN MARKET
 
 
 
 
TABLE 48
MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 49
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 50
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 51
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 52
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 53
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 54
KEY POC TESTING PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 55
MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 56
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 57
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 58
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 59
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 60
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 61
MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 62
KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 63
MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 64
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 65
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 66
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 67
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 68
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 69
KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 70
MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 71
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 72
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 73
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 74
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 75
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 76
OTHER SAMPLE TYPE-BASED PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 77
MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 78
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 79
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 80
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 81
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 82
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 83
MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 84
KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE IN MARKET
 
 
 
 
TABLE 85
MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 86
MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 87
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 88
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 89
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 90
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 91
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 92
KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE IN MARKET
 
 
 
 
TABLE 93
MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 94
MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 95
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 96
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 97
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 98
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 99
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 100
KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE IN MARKET
 
 
 
 
TABLE 101
MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 102
MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 103
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 104
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 105
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 106
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 107
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 108
KEY IN SITU HYBRIDIZATION PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 109
MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 110
MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 111
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 112
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 113
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 114
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 115
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 116
KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 117
MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 118
MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 119
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 120
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 121
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 122
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 123
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 124
MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 125
MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 126
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 127
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 128
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 129
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 130
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 131
MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 132
KEY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 133
MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 134
MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 135
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 136
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 137
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 138
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 139
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 140
MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 141
MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 142
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 143
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 144
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 145
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 146
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 147
KEY CT/NG MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 148
MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 149
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 150
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 151
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 152
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 153
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 154
KEY HIV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 155
MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 156
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 157
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 158
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 159
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 160
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 161
KEY HPV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 162
MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 163
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 164
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 165
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 166
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 167
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 168
KEY SYPHILIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 169
MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 170
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 171
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 172
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 173
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 174
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 175
OTHER SEXUALLY TRANSMITTED DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 176
MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 177
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 178
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 179
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 180
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 181
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 182
KEY HEPATITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 183
MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 184
MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 185
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 186
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 187
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 188
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 189
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 190
MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 191
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 192
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 193
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 194
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 195
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 196
MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 197
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 198
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 199
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 200
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 201
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 202
MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 203
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 204
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 205
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 206
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 207
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 208
MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 209
MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 210
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 211
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 212
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 213
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 214
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 215
KEY TUBERCULOSIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 216
MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 217
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 218
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 219
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 220
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 221
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 222
GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (MILLIONS)
 
 
 
 
TABLE 223
KEY INFLUENZA MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 224
MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 225
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 226
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 227
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 228
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 229
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 230
KEY PHARYNGITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 231
MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 232
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 233
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 234
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 235
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 236
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PHARYNGITIS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 237
OTHER RESPIRATORY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 238
MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 239
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 240
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 241
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 242
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 243
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 244
KEY HOSPITAL-ACQUIRED INFECTION-BASED MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 245
MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 246
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 247
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 248
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 249
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 250
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 251
KEY VECTOR-BORNE DISEASES DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 252
MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 253
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 254
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 255
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 256
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 257
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 258
GLOBAL CASES OF ACTIVE SYPHILIS IN AGE GROUP FROM 15 TO 49 YEARS, 2016–2022 (THOUSANDS)
 
 
 
 
TABLE 259
OTHER INFECTIOUS DISEASE MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 260
MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 261
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 262
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 263
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 264
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 265
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 266
KEY ONCOLOGY TESTING PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 267
MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 268
MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 269
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 270
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 271
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 272
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 273
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 274
BREAST CANCER INCIDENCE, BY REGION, 2022 VS. 2030
 
 
 
 
TABLE 275
MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 276
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 277
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 278
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 279
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 280
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 281
COLORECTAL CANCER INCIDENCE, BY REGION, 2022 VS. 2030
 
 
 
 
TABLE 282
MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 283
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 284
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 285
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 286
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 287
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 288
LUNG CANCER INCIDENCE, BY REGION, 2022 VS. 2030
 
 
 
 
TABLE 289
MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 290
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 291
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 292
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 293
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 294
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 295
PROSTATE CANCER INCIDENCE, BY REGION, 2022 VS. 2030
 
 
 
 
TABLE 296
MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 297
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 298
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 299
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 300
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 301
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 302
GLOBAL INCIDENCE OF OTHER CANCER TYPES, 2022 VS. 2030
 
 
 
 
TABLE 303
MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 304
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 305
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 306
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 307
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 308
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 309
KEY GENETIC TESTING PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 310
MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 311
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 312
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 313
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 314
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 315
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 316
MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 317
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 318
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 319
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 320
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 321
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 322
MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 323
KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 324
MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 325
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 326
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 327
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 328
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 329
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR MULTIPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 330
KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 331
MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 332
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 333
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 334
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 335
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 336
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SINGLEPLEX TESTING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 337
MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 338
KEY DIAGNOSTIC PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 339
MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 340
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 341
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 342
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 343
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 344
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 345
KEY SCREENING PRODUCTS AVAILABLE IN MARKET
 
 
 
 
TABLE 346
MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 347
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 348
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 349
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 350
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 351
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 352
MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 353
MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 354
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 355
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 356
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 357
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 358
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 359
MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 360
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 361
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 362
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 363
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 364
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 365
MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 366
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 367
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 368
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 369
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 370
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 371
PROJECTED CANCER CASES, BY COUNTRY, 2030
 
 
 
 
TABLE 372
MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 373
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 374
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 375
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 376
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 377
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 378
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 379
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 380
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 381
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 382
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 383
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 384
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 385
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 386
US: CANCER CASES AND MORTALITY, BY CANCER TYPE, 2022 VS. 2030
 
 
 
 
TABLE 387
US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 388
US: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 389
US: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 390
US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 391
US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 392
US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 393
US: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 394
US: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 395
US: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 396
US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 397
US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 398
CANADA: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 399
CANADA: FIVE COMMON CANCER TYPES AND DEATH PERCENTAGE
 
 
 
 
TABLE 400
CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 401
CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 402
CANADA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 403
CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 404
CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 405
CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 406
CANADA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 407
CANADA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 408
CANADA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 409
CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 410
CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 411
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 412
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 413
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 414
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 415
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 416
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 417
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 418
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 419
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 420
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 421
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 422
EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 423
EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 424
GERMANY: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 425
GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 426
GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 427
GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 428
GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 429
GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 430
GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 431
GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 432
GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 433
GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 434
GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 435
GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 436
UK: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 437
UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 438
UK: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 439
UK: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 440
UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 441
UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 442
UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 443
UK: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 444
UK: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 445
UK: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 446
UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 447
UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 448
FRANCE: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 449
FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 450
FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 451
FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 452
FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 453
FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 454
FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 455
FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 456
FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 457
FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 458
FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 459
FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 460
ITALY: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 461
ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 462
ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 463
ITALY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 464
ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 465
ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 466
ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 467
ITALY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 468
ITALY: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 469
ITALY: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 470
ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 471
ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 472
SPAIN: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 473
SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 474
SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 475
SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 476
SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 477
SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 478
SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 479
SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 480
SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 481
SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 482
SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 483
SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 484
RUSSIA: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 485
RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 486
RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 487
RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 488
RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 489
RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 490
RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 491
RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 492
RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 493
RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 494
RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 495
RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 496
SWITZERLAND: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 497
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 498
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 499
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 500
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 501
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 502
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 503
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 504
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 505
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 506
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 507
SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 508
REST OF EUROPE: PROJECTED CANCER CASES, BY COUNTRY, 2030
 
 
 
 
TABLE 509
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 510
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 511
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 512
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 513
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 514
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 515
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 516
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 517
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 518
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 519
REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 520
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 521
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 522
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 523
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 524
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 525
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 526
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 527
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 528
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 529
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 530
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 531
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 532
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 533
CHINA: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 534
CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 535
CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 536
CHINA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 537
CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 538
CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 539
CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 540
CHINA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 541
CHINA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 542
CHINA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 543
CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 544
CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 545
JAPAN: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 546
JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 547
JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 548
JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 549
JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 550
JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 551
JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 552
JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 553
JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 554
JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 555
JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 556
JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 557
INDIA: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 558
INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 559
INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 560
INDIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 561
INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 562
INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 563
INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 564
INDIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 565
INDIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 566
INDIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 567
INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 568
INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 569
AUSTRALIA: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 570
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 571
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 572
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 573
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 574
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 575
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 576
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 577
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 578
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 579
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 580
AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 581
SOUTH KOREA: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 582
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 583
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 584
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 585
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 586
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 587
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 588
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 589
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 590
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 591
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 592
SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 593
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 594
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 595
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 596
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 597
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 598
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 599
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 600
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 601
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 602
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 603
REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 604
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 605
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 606
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 607
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 608
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 609
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 610
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 611
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 612
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 613
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 614
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 615
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 616
LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 617
BRAZIL: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 618
BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 619
BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 620
BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 621
BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 622
BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 623
BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 624
BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 625
BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 626
BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 627
BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 628
BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 629
MEXICO: PROJECTED CANCER CASES, BY TYPE, 2030
 
 
 
 
TABLE 630
MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 631
MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 632
MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 633
MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 634
MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 635
MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 636
MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 637
MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 638
MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 639
MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 640
MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 641
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 642
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 643
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 644
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 645
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 646
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 647
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 648
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 649
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 650
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 651
REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 652
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
 
 
 
 
TABLE 653
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 654
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 655
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 656
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 657
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 658
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 659
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 660
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 661
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 662
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 663
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 664
MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 665
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 666
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 667
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 668
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 669
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 670
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 671
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 672
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 673
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 674
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 675
SAUDI ARABIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 676
UAE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 677
UAE: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 678
UAE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 679
UAE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 680
UAE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 681
UAE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 682
UAE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 683
UAE: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 684
UAE: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 685
UAE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 686
UAE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 687
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 688
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 689
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 690
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 691
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 692
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 693
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 694
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 695
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 696
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 697
REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 698
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021−JULY 2025
 
 
 
 
TABLE 699
MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
 
 
 
 
TABLE 700
MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT
 
 
 
 
TABLE 701
MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
 
 
 
 
TABLE 702
MOLECULAR DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT
 
 
 
 
TABLE 703
MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
 
 
 
 
TABLE 704
MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
TABLE 705
MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
 
 
 
 
TABLE 706
MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
 
 
 
 
TABLE 707
MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 708
MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 709
MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 710
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 711
DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 712
DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 713
DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 714
DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 715
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
 
 
 
 
TABLE 716
F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 717
F. HOFFMANN-LA ROCHE LTD: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 718
F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 719
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 720
ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 721
ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 722
ILLUMINA, INC.: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 723
ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 724
HOLOGIC, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 725
HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 726
HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 727
HOLOGIC, INC.: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 728
BIOMÉRIEUX: COMPANY OVERVIEW
 
 
 
 
TABLE 729
BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 730
BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 731
BIOMÉRIEUX: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 732
ABBOTT LABORATORIES: COMPANY OVERVIEW
 
 
 
 
TABLE 733
ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 734
ABBOTT LABORATORIES: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 735
ABBOTT LABORATORIES: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 736
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 737
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 738
THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 739
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 740
QIAGEN N.V.: COMPANY OVERVIEW
 
 
 
 
TABLE 741
QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 742
QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 743
QIAGEN N.V.: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 744
QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 745
REVVITY, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 746
REVVITY, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 747
MYRIAD GENETICS, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 748
MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 749
MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 750
MYRIAD GENETICS, INC.: DEALS, JANUARY 2021- JULY 2025
 
 
 
 
TABLE 751
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 
 
 
 
TABLE 752
SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
 
 
 
 
TABLE 753
SIEMENS HEALTHINEERS AG: PRODUCT/SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–JULY 2025
 
 
 
 
TABLE 754
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 755
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021– JULY 2025
 
 
 
 
TABLE 756
BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
 
 
 
 
TABLE 757
GRIFOLS, S.A.: COMPANY OVERVIEW
 
 
 
 
TABLE 758
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 759
DIASORIN S.P.A.: COMPANY OVERVIEW
 
 
 
 
TABLE 760
EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 761
GENETIC SIGNATURES: COMPANY OVERVIEW
 
 
 
 
TABLE 762
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 763
MDXHEALTH: COMPANY OVERVIEW
 
 
 
 
TABLE 764
BIOCARTIS: COMPANY OVERVIEW
 
 
 
 
TABLE 765
MEDIGEN BIOTECHNOLOGY CORP.: COMPANY OVERVIEW
 
 
 
 
TABLE 766
VELA DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 767
AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 768
BRUKER CORPORATION (ELITECHGROUP): COMPANY OVERVIEW
 
 
 
 
TABLE 769
MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
 
 
 
 
TABLE 770
GENEOMBIOTECHNOLOGIES: COMPANY OVERVIEW
 
 
 
 
TABLE 771
SAVYON DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 772
UNIOGEN OY: COMPANY OVERVIEW
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
FIGURE 1
RESEARCH DESIGN METHODOLOGY
 
 
 
 
FIGURE 2
KEY PRIMARY SOURCES
 
 
 
 
FIGURE 3
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
FIGURE 5
BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
 
 
 
 
FIGURE 6
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
FIGURE 7
MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
 
 
 
 
FIGURE 8
DATA TRIANGULATION METHODOLOGY
 
 
 
 
FIGURE 9
MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
 
 
 
 
FIGURE 10
MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 11
MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 12
MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 13
MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 14
MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 15
MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 16
MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 17
MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 18
MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 19
INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET
 
 
 
 
FIGURE 20
REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 21
LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 22
BLOOD, SERUM, AND PLASMA SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 23
POLYMERASE CHAIN REACTION SEGMENT TO ACHIEVE LARGEST SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 24
INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 25
MULTIPLEX TESTING SEGMENT TO ACCOUNT FOR SIGNIFICANT SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 26
DIAGNOSTIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
FIGURE 27
DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET IN 2030
 
 
 
 
FIGURE 28
NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 29
MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
FIGURE 30
INCIDENCE OF HIV, BY REGION, 2024
 
 
 
 
FIGURE 31
PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES, JANUARY 2015–DECEMBER 2024
 
 
 
 
FIGURE 32
MOLECULAR DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
FIGURE 33
MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
FIGURE 34
MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
FIGURE 35
MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
FIGURE 36
MOLECULAR DIAGNOSTICS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
FIGURE 37
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
 
 
 
 
FIGURE 38
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
 
 
 
 
FIGURE 39
NUMBER OF DEALS & TOTAL FUNDING, 2021–2025
 
 
 
 
FIGURE 40
MOLECULAR DIAGNOSTICS MARKET: KEY USE CASES
 
 
 
 
FIGURE 41
NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
FIGURE 42
ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
FIGURE 43
REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION)
 
 
 
 
FIGURE 44
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
 
 
 
 
FIGURE 45
MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
FIGURE 46
MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT
 
 
 
 
FIGURE 47
MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
FIGURE 48
EV/EBITDA OF KEY VENDORS
 
 
 
 
FIGURE 49
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
FIGURE 50
BRAND/PRODUCT COMPARISON FOR MOLECULAR DIAGNOSTIC INSTRUMENTS
 
 
 
 
FIGURE 51
DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 52
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 53
ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 54
HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 55
BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 56
ABBOTT LABORATORIES: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 57
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 58
QIAGEN N.V.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 59
REVVITY, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 60
MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
FIGURE 61
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
 
 
 
 

Methodology

The study involved major activities in estimating the current market size for the global molecular diagnostics market. Exhaustive secondary research was done to collect information on the molecular diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular diagnostics market.

The four steps involved in estimating the market size are as follows:

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

Breakdown Of Primary Participants

Molecular Diagnostics Market

Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.

Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers:

Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.

  • The key players in the industry have been identified through extensive secondary research.
  • Primary and secondary research have determined the revenues generated by leading players operating in the molecular diagnostics market.
  • All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Molecular Diagnostics Market

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.

Stakeholders

  • Senior Management
  • End Users
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global molecular diagnostics market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
  • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
  • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall molecular diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
  • To study the impact of AI/Gen AI on the molecular diagnostics market, along with the macroeconomic outlook for each region

 

Key Questions Addressed by the Report

What are the recent trends affecting the molecular diagnostics market?

Key trends shaping the molecular diagnostics market include the global rise in life-threatening infectious diseases caused by pathogenic microorganisms, increasing government initiatives that promote R&D activities, and growing public awareness regarding the benefits of early disease detection.

Which test types are covered in the molecular diagnostics market report?

The two main test types covered in this study are lab and PoC. In 2024, the lab tests segment accounted for a significant market share, driven by increasing demand for automated workflows and a rising prevalence of infectious diseases. Additionally, technological advancements in diagnostic platforms have significantly contributed to the growth of the segment.

Who are the key players in the molecular diagnostics market?

The key players in this market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), Hologic, Inc. (US), Abbott (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), Revvity (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), and DiaSorin S.p.A. (Italy).

Which techniques are covered in the molecular diagnostics market report?

The two main techniques this report covers are multiplex testing and singleplex testing. In 2024, the multiplex testing segment accounted for a significant share of the global market. Its dominance was primarily driven by the technique’s ability to simultaneously detect multiple targets in a single assay, enhancing diagnostic accuracy and reducing turnaround time.

Which region is lucrative for the molecular diagnostics market?

Asia Pacific, led by rapidly developing healthcare systems, represents a high-growth region for the molecular diagnostics market. Factors such as expanding healthcare infrastructure, increasing investments in diagnostic technologies, and a growing patient population are creating substantial market opportunities across the region.

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Molecular Diagnostics Market

MnM

Jun, 2022

• Due to covid, there was an increase in the demand for immunodiagnostics and molecular testing, which was regarded as the gold standard for diagnosing infectious diseases, leading to the increased sales of related consumables and kits. During the pandemic era, revenue growth for key players was majorly driven by the sales of COVID-19 diagnostic tests. The dominant model of laboratory testing throughout the world remains the centralized laboratory that uses automated analytical testing methods to detect target analytes. This trend is well established in clinical chemistry and haematology disciplines and is now extending to other areas, including immunoassays and molecular diagnostics. Reagents & kits segment accounted for the largest share in the IVD market and Oncology segment is expected to witness the fastest growth in the forecast period. With 30,000+ partners, technologies, and use-cases as the primary levers, we have deep understanding of IVD ecosystem. We offer more than 2X coverage throughout the IVD curve as compared to our competitors..

MnM

Jun, 2022

•The molecular diagnostics market is segmented into lab tests and PoC tests by test type. The lab tests segment accounted for the largest share of the molecular diagnostics market in 2021. Factors such as the increasing need for automation and the rising incidence of various infectious diseases are driving the growth of this segment. •Molecular diagnostic reagents include disease-specific kits and general reagents used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more accurate identification of specific pathogen strains in a patient sample. General reagents are key components of a majority of conventional molecular diagnostic procedures. • Companies are now launching rapid kits and reagents to detect the novel coronavirus, which is further fueling the growth of this market segment. Regional authorities have also been actively engaged in providing emergency approvals for the use of these kits. In September 2020, Danaher Corporation (US) received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for the qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. In March 2020, QIAGEN N.V. (Netherlands) received FDA approval for its QIAstat-Dx test kit to detect coronavirus. .

DMCA.com Protection Status